Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

被引：2

作者：

Tanioka, M.

Fan, C.

Carey, L. A.

Hyslop, T.

Pitcher, B. N.

Parker, J. A.

Hoadley, K. A.

Henry, N. L.

Tolaney, S.

Dang, C.

Krop, I. E.

Harris, L.

Berry, D. A.

Mardis, E.

Perou, C. M.

Winer, E. P.

Hudis, C. A.

机构：

[1] Univ N Carolina, Chapel Hill, NC USA

[2] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] NCI, Bethesda, MD 20892 USA

[7] Alliance Stat & Data Ctr MD Anderson, Houston, TX USA

[8] Washington Univ, St Louis, MO USA

来源：

CANCER RESEARCH | 2017年 / 77卷

关键词：

D O I：

10.1158/1538-7445.SABCS16-S3-05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

S3-05

引用

页数：2

共 50 条

[41] Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
Ollila, David W.
Cirrincione, Constance T.
Berry, Donald A.
Carey, Lisa A.
Sikov, William M.
Hudis, Clifford A.
Winer, Eric P.
Golshan, Mehra
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 224 (04) : 688 - 694
[42] A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
Tolaney, S. M.
Barry, W. T.
Dang, C. T.
Yardley, D. A.
Moy, B.
Marcom, P. K.
Albain, K. S.
Rugo, H. S.
Ellis, M.
Shapira, I.
Wolff, A. C.
Carey, L. A.
Overmoyer, B. A.
Partridge, A. H.
Guo, H.
Hudis, C. A.
Krop, I. E.
Burstein, H. J.
Winer, E. P.
CANCER RESEARCH, 2013, 73
[43] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Hurvitz, Sara A.
Caswell-Jin, Jennifer L.
McNamara, Katherine L.
Zoeller, Jason J.
Bean, Gregory R.
Dichmann, Robert
Perez, Alejandra
Patel, Ravindranath
Zehngebot, Lee
Allen, Heather
Bosserman, Linda
DiCarlo, Brian
Kennedy, April
Giuliano, Armando
Calfa, Carmen
Molthrop, David
Mani, Aruna
Chen, Hsiao-Wang
Dering, Judy
Adams, Brad
Kotler, Eran
Press, Michael F.
Brugge, Joan S.
Curtis, Christina
Slamon, Dennis J.
NATURE COMMUNICATIONS, 2020, 11 (01)
[44] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Sara A. Hurvitz
Jennifer L. Caswell-Jin
Katherine L. McNamara
Jason J. Zoeller
Gregory R. Bean
Robert Dichmann
Alejandra Perez
Ravindranath Patel
Lee Zehngebot
Heather Allen
Linda Bosserman
Brian DiCarlo
April Kennedy
Armando Giuliano
Carmen Calfa
David Molthrop
Aruna Mani
Hsiao-Wang Chen
Judy Dering
Brad Adams
Eran Kotler
Michael F. Press
Joan S. Brugge
Christina Curtis
Dennis J. Slamon
Nature Communications, 11
[45] Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
Loibl, S.
Jackisch, J.
Schneeweiss, A.
Schmatloch, S.
Aktas, B.
Denkert, C.
Schem, C.
Wiebringhaus, H.
Kuemmel, S.
Luebbe, K.
Warm, M.
Just, M.
Hanusch, C.
Hackmann, J.
Blohmer, J-U
Clemens, M.
Engels, K.
Nekljudova, V.
von Minckwitz, G.
Untch, M.
CANCER RESEARCH, 2017, 77
[46] Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
Xu, B.
Yan, M.
Ma, F.
Li, W.
Ouyang, Q.
Tong, Z.
Teng, Y.
Wang, S.
Wang, Y.
Geng, C.
Luo, T.
Zhong, J.
Zhang, Q.
Liu, Q.
Zeng, X.
Sun, T.
Mo, Q.
Dong, F.
Wu, S.
Zhu, X.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1387 - S1387
[47] First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
CANCER RESEARCH, 2010, 70
[48] Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
Loibl, S.
Jackisch, C.
Schneeweiss, A.
Schmatloch, S.
Aktas, B.
Denkert, C.
Wiebringhaus, H.
Kuemmel, S.
Warm, M.
Paepke, S.
Just, M.
Hanusch, C.
Hackmann, J.
Blohmer, J. -U.
Clemens, M.
Costa, S. Dan
Gerber, B.
Engels, K.
Nekljudova, V.
von Minckwitz, G.
Untch, M.
ANNALS OF ONCOLOGY, 2017, 28 (03) : 497 - 504
[49] Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Jiong Wu
Zefei Jiang
Zhenzhen Liu
Benlong Yang
Hongjian Yang
Jinhai Tang
Kun Wang
Yunjiang Liu
Haibo Wang
Peifen Fu
Shuqun Zhang
Qiang Liu
Shusen Wang
Jian Huang
Chuan Wang
Shu Wang
Yongsheng Wang
Linlin Zhen
Xiaoyu Zhu
Fei Wu
Xiang Lin
Jianjun Zou
BMC Medicine, 20
[50] Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Wu, Jiong
Jiang, Zefei
Liu, Zhenzhen
Yang, Benlong
Yang, Hongjian
Tang, Jinhai
Wang, Kun
Liu, Yunjiang
Wang, Haibo
Fu, Peifen
Zhang, Shuqun
Liu, Qiang
Wang, Shusen
Huang, Jian
Wang, Chuan
Wang, Shu
Wang, Yongsheng
Zhen, Linlin
Zhu, Xiaoyu
Wu, Fei
Lin, Xiang
Zou, Jianjun
BMC MEDICINE, 2022, 20 (01)

← 1 2 3 4 5 →